Opioids With Abuse-Deterrent Labeling
This article was originally published in The Pink Sheet Daily
Only two of the six ER/LA opioids approved with abuse-deterrent labeling target the oral route of abuse.
You may also be interested in...
Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.
Inability to chew Arymo ER tablet helps Egalet overcome questions about clinical meaningfulness of human oral abuse study results; advisors also back intranasal, intravenous deterrence claims.
Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.